Overview

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin disease (CAD).
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Swedish Orphan Biovitrum
Criteria
Inclusion Criteria:

1. Age 18 years or older.

2. Diagnosis of primary CAD.

3. Hb level ≤ 9 g/dL.

4. Documented results from bone marrow biopsy within 1 year of screening

5. Either have vaccination against Streptococcus pneumoniae, Neisseria meningitidis
(Types A, C, W, Y, and B), and Haemophilus influenzae (Type B) within 2 years prior to
screening or agree to receive vaccination during screening.

6. Women of childbearing potential (WOCBP), defined as any women who have experienced
menarche and who are NOT permanently sterile or postmenopausal, must have a negative
pregnancy test at screening and agree to use protocol-defined methods of contraception
for the duration of the study and 8 weeks after their last IMP dose.

7. Men must agree to the following for the duration of the study and 8 weeks after their
last IMP dose:

1. Avoid fathering a child.

2. Use protocol-defined methods of contraception.

3. Refrain from donating sperm.

8. Willing and able to give written informed consent.

Exclusion Criteria:

1. Have received other anti-complement therapies (approved or investigational) within 5
half-lives of the agent prior to randomization.

2. Treatment with rituximab monotherapy within 12 weeks prior to randomization, or
rituximab combination therapies (e.g., with bendamustine, fludarabine, other cytotoxic
drugs or ibrutinib) within 16 weeks prior to randomization.

3. Diagnosis of systemic lupus erythematosus or other autoimmune diseases with
antinuclear antibodies.

4. History of an aggressive lymphoma or presence of a lymphoma requiring therapy.

5. Have received an organ transplant.

6. Cold agglutinin syndrome secondary to Mycoplasma pneumoniae, Epstein-Barr virus or
other specific causative infection.

7. Presence or suspicion of liver dysfunction as indicated by elevated alanine
aminotransferase (ALT) > 2.5 x ULN, or direct bilirubin levels > 2 x ULN.

8. Inability to cooperate with study procedures.